KPI-287

KPI-287 is an investigational **small-molecule receptor tyrosine kinase inhibitor** that was being developed by Kala Pharmaceuticals for retinal vascular diseases. Publicly available company and pipeline materials describe it as a preclinical ophthalmology asset intended to inhibit vascular endothelial growth factor and platelet-derived growth factor signaling, with proposed use in disorders such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and more broadly retinal diseases. Available secondary sources indicate activity against VEGF receptor family members and note additional off-target kinase-related pharmacology, but the exact intended primary target profile and clinical formulation were not clearly established in authoritative primary documentation. Kala later discontinued development of KPI-287 as part of a strategic reprioritization of its pipeline.